Product Center
Recombinant Herpes Zoster Vaccine (CHO Cell) IND Application Accepted
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-02-23
- Views:
(Summary description)On February 23, 2024, Ab&B Bio Tech Co., Ltd. JS independently developed a Class I new drug, the recombinant herpes zoster vaccine (CHO cell), whose IND application was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
Recombinant Herpes Zoster Vaccine (CHO Cell) IND Application Accepted
(Summary description)On February 23, 2024, Ab&B Bio Tech Co., Ltd. JS independently developed a Class I new drug, the recombinant herpes zoster vaccine (CHO cell), whose IND application was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-02-23 16:13
- Views:
Herpes zoster (HZ) is an infectious disease that mainly affects nerves and skin, caused by reactivation of the varicella-zoster virus (VZV). Its main characteristics are clustered blisters distributed in a stripe-like pattern, accompanied by significant neuralgia. The older the age, the more severe the neuralgia. This disease is common in older adults, immunocompromised individuals, and those using immunosuppressants, and has a certain recurrence rate. Currently, there is no effective treatment for herpes zoster, and vaccination is the most effective means of prevention.
Ab&B Bio Tech Co., Ltd. JS adheres to the principle of avoiding simple replication and focuses on independent innovation in research and development. The recombinant herpes zoster vaccine (CHO cells) accepted this time utilizes multiple independent intellectual property innovations, adjuvant systems, and an officially authorized high-expression cell matrix from the company. Preclinical studies have shown that this product can simultaneously induce high levels of specific antibodies and CD4+ T-cell responses, demonstrating high immunogenicity, efficacy, and safety.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
